Breaking News Instant updates and real-time market news.

BAC

Bank of America

$28.42

0.07 (0.25%)

, MRK

Merck

$69.77

1.41 (2.06%)

07:35
10/15/18
10/15
07:35
10/15/18
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Friday in Bank of America (BAC), Merck (MRK), Zions Bancorp (ZION), Energy Transfer Partners (ETP), Cenovus Energy (CVE), First Majestic (AG), KeyCorp (KEY), Penn National (PENN), Century Communities (CCS), and Ferro (FOE).

BAC

Bank of America

$28.42

0.07 (0.25%)

MRK

Merck

$69.77

1.41 (2.06%)

ZION

Zions Bancorp

$48.26

-0.93 (-1.89%)

ETP

Symbol now ET

$21.66

0.3 (1.40%)

CVE

Cenovus Energy

$8.76

-0.21 (-2.34%)

AG

First Majestic

$6.16

-0.05 (-0.81%)

KEY

KeyCorp

$18.66

-0.58 (-3.01%)

PENN

Penn National

$29.91

1.33 (4.65%)

CCS

Century Communities

$23.45

-0.09 (-0.38%)

FOE

Ferro

$18.60

-0.77 (-3.98%)

  • 15

    Oct

  • 17

    Oct

  • 18

    Oct

  • 18

    Oct

  • 19

    Oct

  • 19

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 29

    Oct

  • 30

    Oct

  • 06

    Nov

  • 13

    Nov

  • 16

    Nov

  • 04

    Dec

  • 11

    Jan

  • 16

    Feb

BAC Bank of America
$28.42

0.07 (0.25%)

09/19/18
OPCO
09/19/18
NO CHANGE
OPCO
Outperform
U.S. banks 'in very good shape,' says Oppenheimer, favorites include BofA, Citi
Oppenheimer analyst Chris Kotowski tells investors in a research note that the U.S. banking group is on solid footing with balance sheets less risky than at any time over the last 33 years the firm covered the group and says his favorite bank stocks are Outperform-rated Bank of America (BAC), Citi (C), CIT (CIT) and Goldman Sachs (GS). However, Kotowski notes that banks are trading at an average relative P/E of just ~66% relative to the S&P 500 and returning to a historical avg valuation of 73%-80% range would imply over a thousand basis points of outperformance by the group. In his view, the U.S. banks are, on the whole, in "very good" shape.
09/25/18
WOLF
09/25/18
INITIATION
Target $40
WOLF
Outperform
Bank of America initiated with an Outperform at Wolfe Research
Wolfe Research analyst Steven Chubak initiated Bank of America with an Outperform and $40 price target.
07/17/18
BARD
07/17/18
NO CHANGE
Target $30
BARD
Neutral
Baird would be buyers of Bank of America on weakness
Baird analyst David George said he would remain a buyer of Bank of America shares on any weakness, stating that its operating leverage was impressive in Q2 and should continue along with solid execution. George maintained his Neutral rating and $30 price target on Bank of America shares.
07/09/18
GSCO
07/09/18
NO CHANGE
GSCO
Bank of America, Morgan Stanley top ideas into Q2 earnings season, says Goldman Sachs
Goldman Sachs analyst Richard Ramsden expects Bank of America (BAC) and Morgan Stanley (MS) to beat consensus estimates in Q2. The analyst argues that both appear best positioned, while he sees risk for U.S. Bancorp (USB) and JPMorgan (JPM). Ramsden highlights Bank of America given the material valuation dislocation that looks to support the stock over time. Additionally, the analyst expects an expense and NII beat for Morgan Stanley.
MRK Merck
$69.77

1.41 (2.06%)

10/03/18
HCWC
10/03/18
NO CHANGE
Target $4
HCWC
Buy
H.C. Wainwright positive on BioLineRx economic stake increase in BL-8040
H.C. Wainwright analyst Joseph Pantginis notes that BioLineRx (BLRX) announced the increase of its economic stake in BL-8040 from 60% to 80% from Biokine Therapeutics. The analyst believes that this transaction should signal increased confidence to investors as to the company's increased investment into BL-8040. Additionally, Pantginis argues that COMBAT data at ESMO later this month represents a potential tipping point for shares. COMBAT is a Phase 2a open-label study evaluating the safety and efficacy of BL-8040 in combination with pembrolizumab in patients with advanced pancreatic cancer in collaboration with Merck (MRK). He reiterates a Buy rating and $4 price target on BioLineRx shares.
10/08/18
GUGG
10/08/18
INITIATION
Target $84
GUGG
Buy
Merck initiated with a Buy at Guggenheim
Guggenheim analyst Seamus Fernandez started Merck with a Buy rating and $84 price target, citing the sales and EPS upside he sees as Keytruda growth expands in the U.S. and globally. He also sees some partner products, such as Lynparza and Lenvima, along with the company's pipeline as being underappreciated, Fernandez tells investors.
10/11/18
FBCO
10/11/18
NO CHANGE
Target $81
FBCO
Outperform
Merck price target raised to $81 from $71 at Credit Suisse
Credit Suisse analyst Vamil Divan raised his price target for Merck to $81 from $71, while reiterating an Outperform rating on the shares. While the shares have had a significant move this year, the analyst sees room for additional upside as the company continues to roll out Keytruda, most notably in the 1st line non-small cell lung setting. However, Divan also acknowledges longer-term investors remain concerned about how the company will navigate the Januvia patent expiration in mid-2022.
08/23/18
MSCO
08/23/18
NO CHANGE
Target $74
MSCO
Overweight
Merck price target raised to $74 from $68 at Morgan Stanley
Morgan Stanley analyst David Risinger maintained an Overweight rating on Merck and raised his price target to $74 from $68, citing his expectation for operating leverage to become more visible in 2019 and pipeline progress to improve perception about prospects in the face of Januvia generics in January 2023. Looking ahead, Risinger projects Merck's 5-year CAGR from 2018-2023 for revenue growth of 3% and EPS growth of 8%. Risinger says he believes the primary driver of major pharma stock performance in recent months is "defensive rotation." Looking ahead, the analyst says to watch for U.S. pricing perception drivers in the coming months that could impact pharma stock performance, including potential additional HHS action on drug rebates, November election results and manufacturer communication and action on U.S. list prices by early January.
ZION Zions Bancorp
$48.26

-0.93 (-1.89%)

05/14/18
WEDB
05/14/18
INITIATION
WEDB
Neutral
Zions Bancorp initiated with a Neutral at Wedbush
07/10/18
RAJA
07/10/18
UPGRADE
RAJA
Strong Buy
Zions Bancorp upgraded to Strong Buy from Outperform at Raymond James
09/07/18
UBSW
09/07/18
DOWNGRADE
UBSW
Neutral
Zions Bancorp downgraded to Neutral from Buy at UBS
UBS analyst Brock Vandervliet downgraded Zions Bancorp to Neutral.
09/07/18
UBSW
09/07/18
DOWNGRADE
Target $56
UBSW
Neutral
UBS downgrades Zions Bancorp to Neutral with $56 price target
UBS analyst Brock Vandervliet downgraded Zions Bancorp to Neutral from Buy and lowered his price target for the shares to $56 from $67. The analyst had expected mid-single digit loan growth would build to the 6%-8% range after years of drag from energy and commercial real estate loan run-off. However, he now forecasts a 4%-5% level. Vandervliet also expected that raising of the systemically important financial institution threshold would re-focus management on generating higher growth and better efficiency. Recent commentary, however, indicates no change in posture, the analyst contends. He also finds Zions' recent capital announcement "underwhelming" saying it is designed to preserve board flexibility as opposed to making a commitment to maximize return.
ETP Symbol now ET
$21.66

0.3 (1.40%)

08/03/18
MSCO
08/03/18
NO CHANGE
MSCO
Overweight
Energy Transfer targets raised on consolidation benefits at Morgan Stanley
Morgan Stanley analyst Tom Abrams raised his price target on Energy Transfer Equity (ETE) to $21 from $19 and increased his target on Energy Transfer Partners (ETP) to $27 from $22 as he said simplification has improved Energy Transfer's cost of capital and he believes the proposed consolidation of the partnership should improve cash dynamics. Going forward, he sees pro forma Energy Transfer having several themes driving longer term performance, such as the Permian, exports, and NGLs, and views it as one of the better positioned MLPs, Abrams tells investors. He keeps an Overweight rating on Energy Transfer Equity and an Equal Weight rating on Energy Transfer Partners.
08/03/18
WOLF
08/03/18
UPGRADE
WOLF
Outperform
Energy Transfer Partners upgraded to Outperform from Peer Perform at Wolfe Research
08/24/18
USCA
08/24/18
UPGRADE
Target $26
USCA
Overweight
Energy Transfer Partners upgraded to Overweight from Hold at US Capital Advisors
US Capital Advisors analyst Rebecca Followill upgraded Energy Transfer Partners to Overweight and raised her price target for the shares to $26 from $20.
09/04/18
MUFG
09/04/18
INITIATION
Target $22
MUFG
Overweight
USA Compression initiated with an Overweight at MUFG
MUFG analyst Barrett Blaschke initiated USA Compression (USAC) with an Overweight rating and a price target of $22, saying the company has taken a "top spot in one of the less noticed business sub-sectors of the midstream universe following a recent acquisition" of CDM compression assets from Energy Transfer Partners (ETP). The analyst believes that the deal will further reduce the company's leverage while also anticipating a "relatively stable cash flows" thanks to expected rolling renewals of its near-term contracts. Blaschke further states that USA Compression's order backlog is at "historically high levels and the lead time for large horsepower compression units continues to increase".
CVE Cenovus Energy
$8.76

-0.21 (-2.34%)

09/10/18
JPMS
09/10/18
UPGRADE
JPMS
Overweight
Cenovus Energy upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Phil Gresh upgraded Cenovus Energy to Overweight and added the shares to his firm's Analyst Focus List as a value pick. Gresh raised his price target for the shares to C$17 from C$16. The company's rail deal with Canadian National (CNI), as reported Friday by Reuters, and its deleveraging will unlock "cheap" free cash flow yield, the analyst tells investors in a research note.
10/05/18
CIBC
10/05/18
INITIATION
CIBC
Outperformer
Cenovus Energy initiated with an Outperformer at CIBC
09/10/18
09/10/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Foot Locker (FL) upgraded to Outperform from Market Perform at Wells Fargo with analyst Tom Nikic saying after 12-18 months of choppy operating performance, he believes that brighter days are ahead for Foot Locker due primarily to improvement in the Nike-brand (NKE) assortment, an alleviation of the Jordan-brand headwind and an alleviation of the headwinds in Europe. 2. Kennametal (KMT) upgraded to Buy from Neutral at Longbow. 3. Credit Suisse (CS) upgraded to Equal Weight from Underweight at Barclays with analyst Amit Goel saying the risk/reward looks more balanced at current share levels. 4. Cenovus Energy (CVE) upgraded to Overweight from Neutral at JPMorgan with analyst Phil Gresh saying the company's rail deal with Canadian National (CNI) and its deleveraging will unlock "cheap" free cash flow yield. 5. Akamai (AKAM) upgraded to Buy from Neutral at DA Davidson with analyst Mark Kelleher citing his meeting with management last week to discuss its Q2 results and the company direction going into 2019. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/07/18
GSCO
09/07/18
DOWNGRADE
Target $8
GSCO
Sell
Cenovus Energy downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Neil Mehta downgraded Cenovus Energy to Sell and lowered his price target for the shares to $8 from $12. The company remains negatively exposed to a "challenging" West Texas Intermediate -Western Canadian Select macro environment, which will continue until the currently estimated in-service of pipeline expansion projects in 2020, Mehta tells investors in a research note. Further, he believes the acceleration of higher royalty payments will drive margin compression at oil sands assets ahead of prior expectations.
AG First Majestic
$6.16

-0.05 (-0.81%)

08/27/18
08/27/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. First Majestic (AG) upgraded to Outperform from Market Perform at BMO Capital with analyst Ryan Thompson citing his expectations of gross margin improvement following the shutdown of the high-cost La Guitarra mine and the integration of the high-margin San Dimas mine. 2. Papa John's (PZZA) upgraded to Buy from Neutral at Kalinowski with analyst Mark Kalinowski saying he believes the reported hiring of Bank of America and Lazard increases the odds of a favorable outcome over the next 12 months, including the possibility of an acquisition. 3. Portola Pharmaceuticals (PTLA) upgraded to Neutral from Underperform at Credit Suisse with analyst Vamil Divan citing Johnson & Johnson (JNJ) and Bayer's (BAYRY) presentation of disappointing data for Xarelto in the acute medically ill population at ESC. 4. Bancolombia (CIB) upgraded to Neutral from Sell at Citi. 5. AK Steel (AKS) and Steel Dynamics (STLD) were upgraded to Overweight from Equal Weight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/27/18
BMOC
08/27/18
UPGRADE
Target $9.5
BMOC
Outperform
First Majestic upgraded at BMO Capital on margin improvement outlookup
As reported earlier, BMO Capital analyst Ryan Thompson upgraded First Majestic to Outperform from Market Perform and raised his price target to CAD9.50 from CAD8.75. The analyst cites his expectations of gross margin improvement following the shutdown of the high-cost La Guitarra mine and the integration of the high-margin San Dimas mine. Thompson also notes the possibility of a reversal in silver prices given the "crowded short position in precious metals" which would benefit the company.
05/15/18
TDSI
05/15/18
UPGRADE
TDSI
Buy
First Majestic upgraded to Buy from Hold at TD Securities
08/27/18
BMOC
08/27/18
UPGRADE
BMOC
Outperform
First Majestic upgraded to Outperform from Market Perform at BMO Capital
BMO Capital analyst Ryan Thompson upgraded First Majestic Silver to Outperform and raised his price target for the shares to C$9.50f from C$8.75.
KEY KeyCorp
$18.66

-0.58 (-3.01%)

09/18/18
09/18/18
DOWNGRADE

Equal Weight
Morgan Stanley downgrades BankUnited to Equal Weight on midcap bank concerns
As previously reported, Morgan Stanley analyst Ken Zerbe downgraded BankUnited to Equal Weight from Overweight, stating that recent commentary from other midcap banks has been incrementally more negative. Five midcap banks - Associated Banc-Corp (ASB), Comerica (CMA), KeyCorp (KEY), M&T Bank (MTB) and Webster Financial (WBS) - have recently guided for loan growth below expectations and several others flagged headwinds to growth, Zerbe tells investors. The primary headwind is weaker CRE loan growth as non-bank lenders remain highly aggressive with both price and terms, the analyst added. BankUnited's CRE portfolio, at 43% of total loans versus peers at 27%, could be at greater risk of runoff, said Zerbe. He also reduced his expectations at 21 of 28 midcap banks he covers and cut his EPS estimates for 18 of those 28 banks.
06/29/18
DBAB
06/29/18
NO CHANGE
DBAB
Deutsche declares Wells Fargo, SunTrust, Huntington the CCAR winners
Deutsche Bank analyst Matt O'Connor views Wells Fargo (WFC), SunTrust (STI) and Huntington Bancshares (HBAN) as the winners of the Federal Reserve's Comprehensive Capital Analysis and Review. The banks separately disclosed planned dividend increases and buybacks for the next four quarters, O'Connor tells investors in a research note. He points out that while JPMorgan (JPM), KeyCorp (KEY) and M&T Bank (MTB) "all used the mulligan," he does not view this as negative.
09/26/18
GSCO
09/26/18
UPGRADE
Target $196
GSCO
Buy
Goldman says rate hikes halfway through, upgrades M&T Bank to Buy
Goldman Sachs analyst Ryan Nash says his firm's economist is calling for six more rate hikes, two in the second half of 2018 and four more through the end of 2020. With six rate hikes in the books, Goldman believes we are half way through the rate rising cycle, Nash tells investors in a research note. The analyst believes some banks will see upside to revenue growth from rates moving higher. Comerica (CMA), Regions Financial (RF), SunTrust (STI), Citizens Financial (CFG) and KeyCorp (KEY) remain top picks for Nash. He also upgraded M&T Bank (MTB) to Buy from Neutral with 15% upside to his $196 price target. The analyst believes M&T will outperform as the benefits of higher rates exceed market expectations.
10/12/18
STPT
10/12/18
UPGRADE
STPT
Buy
KeyCorp upgraded to Buy from Hold at Standpoint Research
PENN Penn National
$29.91

1.33 (4.65%)

10/11/18
STFL
10/11/18
NO CHANGE
Target $38
STFL
Buy
'Irrational selling' of Penn National presents buying opportunity, says Stifel
Stifel analyst Steven Wieczynski blames recent share weakness in regional gaming names on concerns about the economy, hedge funds exiting the gaming space and investors fleeing over-levered balance sheets given rate fears. However, Penn National has 75% of their debt fixed including lease payments and management expects rising rates to actually be a net positive given their senior-aged average customers will end up with more discretionary income in their wallets, Wieczynski tells investors after meeting with company management. He remains "steadfast" in his support of Penn National shares following his meetings and thinks the "irrational selling" of the stock has created a buying opportunity. The analyst keeps a Buy rating and $38 price target on Penn National.
10/01/18
RHCO
10/01/18
INITIATION
Target $39
RHCO
Buy
Penn National assumed with a Buy at SunTrust
SunTrust analyst Barry Jonas assumed Penn National with a Buy rating and a price target of $39 as part of his broader "U.S. Gaming" coverage transfer research report. The analyst is positive on the company's position as a "best in class regional gaming operator" and its expected transformative acquisition of Pinnacle Entertainment (PNK). Jonas notes that M&A synergies could drive potential upside to Penn National estimates along with "continued margin improvements across its portfolio".
08/28/18
JEFF
08/28/18
NO CHANGE
JEFF
Buy
Penn, Boyd smoking ban weakness may be buying opportunity, says Jefferies
Jefferies analyst David Katz said he views proposed smoking bans in St. Charles and St. Louis counties as potentially detrimental to Penn National (PENN) and Boyd Gaming (BYD), depending on the passing of the bills and the exemptions allowed. While the prospective process could "very modestly" temper his otherwise positive view on both stocks, he would consider any potential weakness a buying opportunity, Katz added. He keeps Buy ratings on the stocks of both casino operators.
07/26/18
UGAM
07/26/18
DOWNGRADE
UGAM
Hold
Penn National downgraded to Hold from Buy at Union Gaming
CCS Century Communities
$23.45

-0.09 (-0.38%)

07/06/18
WEDB
07/06/18
NO CHANGE
Target $42
WEDB
Outperform
Century Communities shares undervalued at current levels, says Wedbush
Wedbush analyst Jay McCanless reiterated an Outperform rating on Century Communities, telling investors in a research note that last month's acquisition of the remaining 50% of Wade Jurney expands the company even deeper into the entry-level/affordable housing space. McCanless says that, at current levels, Century Communities trades at 6.8x his FY19E adjusted EPS of $4.68 vs. the group average of 8.3x, and while he does not see a current or future catalyst for this disparity, he views the shares as undervalued at these levels. The next catalyst for shares should be the June quarter report in early August, he says. The analyst has a $42 price target on shares.
09/21/18
JPMS
09/21/18
DOWNGRADE
Target $31.5
JPMS
Neutral
Century Communities downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Michael Rehaut downgraded Century Communities to Neutral and lowered his price target for the shares to $31.50 from $38.50. The analyst believes the stock's "premium" valuation appropriately reflects the company's recent, solid track record of growth and integration of acquisitions.
06/20/18
ZELM
06/20/18
INITIATION
ZELM
Hold
Century Communities initiated with a Hold at Zelman
06/15/18
WEDB
06/15/18
NO CHANGE
Target $42
WEDB
Outperform
Century Communities may have paid over $15M for WJH stake, says Wedbush
Wedbush analyst Jay McCanless reiterated an Outperform rating and $42 price target on Century Communities following the company's plans to acquire the remaining 50% stake in Wade Jurney Homes. McCanless tells investors that he believes the purchase price for the stake was above the $15M Century paid in 2016 for the first 50% stake and sees the company updating FY guidance on the Q2 conference call. He increased his FY18E/FY19E adjusted EPS estimates to $4.33/$4.68 from $4.24/$4.37.
FOE Ferro
$18.60

-0.77 (-3.98%)

07/13/18
KEYB
07/13/18
NO CHANGE
Target $500
KEYB
Overweight
Sherwin-Williams, Huntsman, Ferro 'top ideas' in Chemicas, says KeyBanc
KeyBanc analyst Michael Sison previewed the Chemicals sector and told investors in a research note that earnings growth for the Chemicals Universe is "heading in the right direction" for 2018, though the sector is off to a relatively flat share price performance through Q2 vs. the S&P 500 +2%. Sison says his checks suggest demand for chemicals remains robust and expects to see mid-single digit organic growth during Q2 and 2H given pricing progress this year. He says his top ideas include Sherwin-Williams (SHW), Huntsman (HUN), Versum Materials (VSM) and Ferro (FOE).
03/27/18
BMOC
03/27/18
INITIATION
Target $29
BMOC
Outperform
Ferro initiated with an Outperform at BMO Capital
BMO Capital analyst John McNulty started Ferro with an Outperform rating and $29 price target.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
10/16/19
10/16
11:17
10/16/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
10/16/19
10/16
11:16
10/16/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRBT

iRobot

$58.99

1.2 (2.08%)

11:15
10/16/19
10/16
11:15
10/16/19
11:15
Options
iRobot put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 13

    Nov

CSCO

Cisco

$46.53

0.16 (0.35%)

11:05
10/16/19
10/16
11:05
10/16/19
11:05
Options
Cisco call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

TMUS

T-Mobile

$79.88

0.13 (0.16%)

, S

Sprint

$6.46

-0.02 (-0.31%)

10:51
10/16/19
10/16
10:51
10/16/19
10:51
Hot Stocks
FCC commissioner Rosenworcel says T-Mobile, Sprint deal will raise prices »

Federal Communications…

TMUS

T-Mobile

$79.88

0.13 (0.16%)

S

Sprint

$6.46

-0.02 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

SIG

Signet Jewelers

$15.36

-0.39 (-2.48%)

10:50
10/16/19
10/16
10:50
10/16/19
10:50
Options
Call volume in Signet Jewelers spikes on large 3-way adjusting long »

Call volume in Signet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Airlines

$89.13

1.23 (1.40%)

10:50
10/16/19
10/16
10:50
10/16/19
10:50
Hot Stocks
United Airlines sees potential for higher fares over holidays »

Management says all hubs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 12

    Nov

INCY

Incyte

$78.05

-0.47 (-0.60%)

10:47
10/16/19
10/16
10:47
10/16/19
10:47
Recommendations
Incyte analyst commentary  »

Incyte REACH2 'a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

PNC

PNC Financial

$143.07

3.51 (2.52%)

10:47
10/16/19
10/16
10:47
10/16/19
10:47
Hot Stocks
Breaking Hot Stocks news story on PNC Financial »

PNC Financial says still…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

PNC

PNC Financial

$143.11

3.55 (2.54%)

10:45
10/16/19
10/16
10:45
10/16/19
10:45
Hot Stocks
Breaking Hot Stocks news story on PNC Financial »

PNC Financial sees one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

PNC

PNC Financial

$143.11

3.55 (2.54%)

10:45
10/16/19
10/16
10:45
10/16/19
10:45
Hot Stocks
Breaking Hot Stocks news story on PNC Financial »

PNC Financial sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

UAL

United Airlines

$89.05

1.15 (1.31%)

, BA

Boeing

$370.43

-0.56 (-0.15%)

10:43
10/16/19
10/16
10:43
10/16/19
10:43
Hot Stocks
Breaking Hot Stocks news story on United Airlines, Boeing »

United Airlines says…

UAL

United Airlines

$89.05

1.15 (1.31%)

BA

Boeing

$370.43

-0.56 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 23

    Oct

  • 12

    Nov

PNC

PNC Financial

$143.12

3.56 (2.55%)

10:43
10/16/19
10/16
10:43
10/16/19
10:43
Hot Stocks
Breaking Hot Stocks news story on PNC Financial »

PNC Financial says on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

UAL

United Airlines

$88.99

1.09 (1.24%)

10:42
10/16/19
10/16
10:42
10/16/19
10:42
Hot Stocks
United Airlines plans to increase aircraft size to help with costs »

Comments provided during…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 12

    Nov

CBRE

CBRE Group

$52.66

0.19 (0.36%)

10:40
10/16/19
10/16
10:40
10/16/19
10:40
Options
Size put roll is legged in CBRE Group »

Size put roll is legged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 11

    Nov

10:35
10/16/19
10/16
10:35
10/16/19
10:35
General news
FX Action: USD-CAD »

FX Action: USD-CAD popped…

PNC

PNC Financial

$142.83

3.27 (2.34%)

10:34
10/16/19
10/16
10:34
10/16/19
10:34
Hot Stocks
PNC Financial notes 'obvious unanswered questions' about operating environment »

Comments taken from Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

ALXN

Alexion

$102.75

-2.095 (-2.00%)

, ACHN

Achillion

$6.34

2.685 (73.46%)

10:31
10/16/19
10/16
10:31
10/16/19
10:31
Recommendations
Alexion, Achillion analyst commentary  »

Piper likes Alexion…

ALXN

Alexion

$102.75

-2.095 (-2.00%)

ACHN

Achillion

$6.34

2.685 (73.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 19

    Oct

  • 23

    Oct

IRBT

iRobot

$59.38

1.59 (2.75%)

10:28
10/16/19
10/16
10:28
10/16/19
10:28
Recommendations
iRobot analyst commentary  »

Citi opens negative…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 13

    Nov

WBA

Walgreens Boots Alliance

$54.85

0.34 (0.62%)

10:25
10/16/19
10/16
10:25
10/16/19
10:25
Options
Walgreen Boots call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

10:25
10/16/19
10/16
10:25
10/16/19
10:25
General news
Treasury Action: yields remain on the richer side »

Treasury Action: yields…

10:25
10/16/19
10/16
10:25
10/16/19
10:25
General news
The U.S. retail sales report undershot estimates »

The U.S. retail sales…

10:25
10/16/19
10/16
10:25
10/16/19
10:25
Conference/Events
House Energy & Commerce Committee to hold a hearing »

The Subcommittee on…

ABC

AmerisourceBergen

$88.20

5.02 (6.04%)

, CAH

Cardinal Health

$50.83

2.9 (6.05%)

10:25
10/16/19
10/16
10:25
10/16/19
10:25
Conference/Events
Wolfe Research healthcare tech analyst to hold an analyst/industry webcast »

Healthcare Technology…

ABC

AmerisourceBergen

$88.20

5.02 (6.04%)

CAH

Cardinal Health

$50.83

2.9 (6.05%)

MCK

McKesson

$148.00

9.83 (7.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 23

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

VZ

Verizon

$60.11

-0.44 (-0.73%)

, CMCSA

Comcast

$45.42

-0.25 (-0.55%)

10:21
10/16/19
10/16
10:21
10/16/19
10:21
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

VZ

Verizon

$60.11

-0.44 (-0.73%)

CMCSA

Comcast

$45.42

-0.25 (-0.55%)

T

AT&T

$37.95

0.045 (0.12%)

INOV

Inovalon

$15.19

0.145 (0.96%)

ASMB

Assembly Biosciences

$10.95

1.65 (17.74%)

CDXC

ChromaDex

$3.19

0.19 (6.33%)

AXSM

Axsome Therapeutics

$20.68

0.03 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 19

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.